Clotrimazole 1% OTC monograph inclusion opposed in McKenna & Cuneo petition.
This article was originally published in The Tan Sheet
Executive Summary
CLOTRIMAZOLE 1% FORMULATION DIFFERENCES MAY EFFECT SAFETY AND EFFICACY, the Washington, D.C.-based law firm McKenna & Cuneo states in an April 22 citizen petition submitted on behalf of an undisclosed client. The petition opposes Schering-Plough's recent request that FDA revise the final monograph for topical antifungal OTC drug products to include clotrimazole 1% ("The Tan Sheet" Dec. 16, 1996, p. 8).